The average time to resistance on buxtinib is around 1 year, but the dose taken can also have an effect on the time to resistance. The average time to resistance for patients taking 90mg of Bugatinib is 9.2 months, while the average time to resistance for patients taking 180mg of Bugatinib per day is 12.9 months. Therefore, when patients take Brugatinib, if they can tolerate the side effects of 180mg, then it will greatly prolong the patient’s resistance time. The drug should be used properly under the guidance of a medical professional. The single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer that is positive for interstitial lymphoma kinase. The recommended dosage regimen for buxtinib is 90mg orally once daily for the first 7 days; if tolerated, the dose can be increased to 180mg orally once daily from day 8 onwards. Patients taking Buxtinib do not have to worry too much about Buxtinib drug resistance within one year, although the above data can be used as a reference, but not absolute, because each person’s condition is different, for the drug absorption of the concentration of different, the specific varies from person to person. Adverse reactions include decreased white blood cell count, hyponatremia, interstitial lung disease or non-infectious pneumonitis, hypertension, bradycardia, visual abnormalities, elevated creatine phosphokinase, elevated pancreatic enzymes, and hyperglycemia. It is contraindicated for those who are allergic to this product and the ingredients contained in it. It is contraindicated in pregnant and lactating women. Bugatinib should be used under the supervision of a physician and should be reviewed regularly.